1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Journal Article

    Pignata, S.; Bookman, M.; Sehouli, J.; Miller, A.; Penson, R. T.; Taskiran, C.; Anderson, C.; Hietanen, S.; Myers, T.; Madry, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 CLEAR study in patients with advanced renal cell carcinoma: Outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Journal Article

    Grünwald, V.; Powles, T.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C.; Motzer, R.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of immediate lymphatic reconstruction to decrease incidence of breast cancer-related lymphedema: Preliminary results of randomized controlled trial
    Conference Paper

    Coriddi, M.; Dayan, J.; Bloomfield, E.; McGrath, L.; Diwan, R.; Monge, J.; Gutierrez, J.; Brown, S.; Boe, L.; Mehrara, B.
    Lippincott Williams & Wilkins (2023)

    Fulltext@MSK | Save
  • A model for the return and referral of all clinically significant secondary findings of genomic sequencing
    Review

    Kodida, R.; Reble, E.; Clausen, M.; Shickh, S.; Mighton, C.; Sam, J.; Forster, N.; Panchal, S.; Aronson, M.; Semotiuk, K.; more...
    Journal of Medical Genetics (2023)

    Fulltext@MSK | Save
  • Background and update for ECOG-ACRIN EA8212: A randomized phase 3 trial of intravesical bacillus Calmette-Guérin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naïve high-grade non–muscle-invasive bladder cancer (BRIDGE)
    Review

    Kates, M.; Chu, X.; Hahn, N.; Pietzak, E.; Smith, A.; Shevrin, D. H.; Crispen, P.; Williams, S. B.; Daneshmand, S.; Packiam, V. T.; more...
    European Urology Focus (2023)

    Fulltext@MSK | Save
  • Re: A comprehensive 6-mo prostate cancer patient empowerment program decreases psychological distress among men undergoing curative prostate cancer treatment: A randomized clinical trial
    Editorial

    Majumdar, J. R.; Carlsson, S. V.
    European Urology (2023)

    Fulltext@MSK | Save
  • Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial
    Journal Article

    Chi, K. N.; Sandhu, S.; Smith, M. R.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Pereira de Santana Gomes, A. J.; Small, E. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Perioperative pembrolizumab for early-stage non-small-cell lung cancer
    Journal Article

    Wakelee, H.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Gao, S.; Chen, K. N.; Dooms, C.; Majem, M.; Eigendorff, E.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial
    Journal Article

    Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Lordick, F.; Van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Health-related quality of life after robotic-assisted vs open radical cystectomy: Analysis of a randomized trial. Reply
    Correspondence

    Clements, M. B.; Beech, B. B.; Atkinson, T. M.; Dalbagni, G. M.; Li, Y.; Vickers, A. J.; Herr, H. W.; Donat, S. M.; Sjoberg, D. D.; Tin, A. L.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save